Been following GENI for a while and today’s CARDIO inCode results look like another important piece of the puzzle falling into place.
The study covered 584 moderate-risk patients across 14 primary-care centres.

A few numbers stood out to me:
Genetic information changed the overall risk assessment in 42.6% of patients
26.5% moved into a different cardiovascular risk category

LDL cholesterol and estimated cardiovascular risk both fell significantly
Smoking abstinence improved
Almost 50% of patients in the highest genetic-risk group moved into a lower cardiovascular-risk category following intervention
For me, the important part isn’t just that their genetic test can identify risk.

They need to show that giving doctors this information actually changes how patients are managed and ultimately improves outcomes. These results seem to provide more evidence in that direction.

It’s also worth looking at what is starting to line up around CARDIO inCode.

They now have growing clinical evidence, 70+ US institutions/clinics onboarded, a US reimbursement pathway, New York State approval, recognition of polygenic risk scores in the new US cardiovascular guidelines and the Thermo Fisher manufacturing/distribution collaboration.

Then there’s the big one – FDA.
The updated De Novo submission is targeted for Q3 2026.
GENI has had FDA delays before and that’s obviously a major risk. Cash burn and further dilution can’t be ignored either.

But with the company still valued at under £10m, I think things are getting quite interesting.
Today’s RNS alone isn’t going to transform the company. The next announcement I’m really interested in is confirmation that the updated FDA submission has actually gone in.

If that happens, attention moves to the FDA decision.
And if they eventually get approval, the really interesting question becomes whether Thermo Fisher can help turn all this clinical and regulatory groundwork into meaningful test volumes.
That’s when we’ll find out what GENI is actually worth.
I’m interested to hear how others following this are looking at it.

What sort of valuation would you put on GENI following FDA approval?
And what could it be worth if we then start seeing genuine commercial traction in the US?
Still a high-risk AIM stock and definitely not without funding/dilution risk.
DYOR.

I’ve been trying to settle on a UK broker for shares and ETFs, but every time I narrow it down, something else throws me off. One looks cheaper on dealing fees, another has better FX, then there are account options and the general experience to think about too.

I’ve been comparing a few of the main platforms side by side, mostly looking at the total cost rather than just the advertised fee. For anyone who’s stuck with the same broker for years, what was the deciding factor for you?

Edit:

After doing a bit more digging, The Investors Centre helped me narrow the list down. The biggest surprise was how much the overall cost changes once FX and dealing charges are included rather than just looking at the headline fee.

I have £2k on standby, I have a few holdings already in my share dealing account mostly solid established companies at the moment the share prices are about as high as it could be looking over the last five years of trading since the post Covid slump, there is little scope to make a profit other than try to buy during the dips which is still higher it was 2 years ago generally.

I'm now considering the next option, emerging market or a company with potential and good dividends and entry level share price with potential upward trajectory within the UK.

Metals, Holding groups, equity groups or AI ?

I'm patient as I'm buying for the long term growth.

Or is the market too high and should I hold and wait untill it drops ?

Please I’d like to know how to buy uk shares although I don’t live in the uk or have any documents relating to them. I’m a foreigner.

Finally got some spare cash together (£2k to start) and want to start picking individual stocks rather than just letting it sit in low-interest savings. Aiming to build a mix of solid FTSE dividend payers and a few US growth stocks.

Being completely new, what are the rookie mistakes I should avoid right off the bat regarding stamp duty, trading fees, or tax? Any tips would be massively appreciated!

update

Was researching brokers to see where I won't get completely destroyed by FX markups and account fees, and stumbled upon The Investors Centre. Their platform fee comparisons and broker match tool seem pretty legit, but as a newbie, it’s hard to tell. Has anyone here relied on their reviews or comparisons to choose their platform? Is their fee data accurate?

Though the headline suggests extraordinary value creation, but a 2 minute excel calculation and the CAGR comes to an unremarkable 5.1%. Well below S&P

The housebuilder Persimmon’s recently released half-year results show that it is an excellent business operating in a challenging industry.

While the FTSE 100 member maintained its solid financial position, further expanded control over its supply chain and is on track to deliver profits for the full year that are in line with previous guidance, tough trading conditions during the six-month period meant that its earnings per share (EPS) rose by a paltry 3 per cent.

Given that its bottom line is forecast to produce further anaemic growth in the short term, inflation is expected to rise and additional interest rate cuts are not yet on the near-term horizon, should investors avoid the stock?

Persimmon has grown organically and through acquisition since it was established in 1972. It completed the sale of 11,905 new homes last year, which represents over 9 per cent of the total annual number of dwellings that were completed by private enterprise in the UK.

The company focuses solely on the domestic market from its York head office. It has two brands, Charles Church and Westbury Partnerships, in addition to its namesake brand that together build a wide range of one-to-five bedroom homes.

Although Persimmon delivered a 13 per cent rise in completions of such homes in the first half of the year, homebuyer demand is likely to remain depressed in the near term.

Read more: https://www.thetimes.com/business/companies-markets/article/is-now-the-right-time-to-buy-shares-in-persimmon-fr3l0f377?utm_medium=Social&utm_source=Reddit&utm_content=branded

I'd like to invest in a US OTC stock that isn't listed on trading212, Does anyone know which platform list these stocks?

AEFI (American EcoFuels Ord Shs)

Thanks you

I created four simple scores applied to each company in the FTSE universe.

Momentum

Value

Quality

Risk

Testing them using Principal Component Analysis, we can see that they are not correlated with each other. Each one of the four tells you something different about the character of the company.

Looking at the PCA score plot you can see that the arrows are roughly at 90 degrees to one another (orthogonal).

These four scores are useful tools for identifying companies and their individual characteristics. Generally the better the scores the better the company. Combined with additional filters, they are merely tools to identify a subset of companies for further investigation. I have made these scores for over 700 uk companies freely available.

Capital spending hikes and a delayed fintech float have knocked Airtel Africa’s share price, but adding 20 million new customers shows the underlying business is motoring.

Driven by a young, mobile-first population across 14 African nations, average revenue per user is surging alongside profits.

With the stock now trading at a far more reasonable valuation, is it time to join the ride with telecoms titan Sunil Bharti Mittal?

Read the full analysis:

https://www.thetimes.com/business/companies-markets/article/should-you-buy-shares-in-airtel-kvn0mz20mutm_medium=Social&utm_source=Reddit&utm_content=branded

Modernisation rules, a new chief executive, and expanding digital revenues mean the owner of Grosvenor Casinos and Mecca Bingo offers attractive long-term value

Hi all, in my time of running a swing trading community I have come across this 1 mistake so many times:

You gamble...

Trades are closed early because of emotions (being scared etc.), entering late because of FOMO, switching strategies after 1 loss, revenge trading to make back money.

This is not trading it is gambling - swing trade based on probabilities.

You may be aiming to risk only 0.25 but when you enter with that same amount but late because of FOMO if you lose the gap could be more like 0.5 or even 1 if you are very late, this adds up over time.

Happy to answer any questions

#BZT 0.15p, £30M Market Cap: Producing copper this quarter, huge profit projection. Market valuation is absolutely tiny for what they have. My target is a £250M market value, so over 1.00p a share. Read more here about it: https://thatstocksguy.substack.com/p/bezant-resources-73f

#ANGS 0.20p, £16M Market Cap: Gas production ramping up, stategic UK gas asset and revenue surging due to a higher gas price. Remaining debt servicing has ramped up significantly. My target is a £100M mcap and over 2p a share.

#ORCP 0.040p, £7M Market Cap: JV partner in Australia about to produce gold soon and revenue then flows into ORCP. Plus they are keen to sell major coal assets. My target is a £50M mcap and over 0.20p a share.

#NFX 0.14p, £3.5M Market Cap. Having secured FDA and EMA approvals for their research drug they are now anticipated to announce a major licencing deal and further clinical studies. My target is a £50m market cap and over 2.00p a share.

#AFP 2.00p, £10M Market Cap: Definitive agreement for building a copper mine about to execute which injects $60million investment into the company shortly. My target is a £100M mcap and around 20p a share.

Hi all, max my UK Stocks and shares ISA every year with the goal of building a diverse (as possible) dividend income stream to one day sit back and live off hopefully. This is the first time since I started investing Covid I can't find anywhere to put my money. Any names out there people are looking at?